Search for potential cholinesterase inhibitors from the zinc database by virtual screening method by Bajda, Marek et al.
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 72 No. 4 pp. 737ñ745, 2015 ISSN 0001-6837
Polish Pharmaceutical Society
Acetylcholinesterase (AChE, EC 3.1.1.7) and
butyrylcholinesterase (BuChE, 3.1.1.8) are enzymes
belonging to a group of serine hydrolases. AChE is
a key enzyme involved in the hydrolysis of acetyl-
choline (ACh) in cholinergic synapses, while
BuChE is able to hydrolyze ACh as well as other
esters. Both enzymes are differentiated on the basis
of their structures, substrate specificities, tissue dis-
tribution and sensitivity to inhibitors (1). The inhibi-
tion of these enzymes causes an increase in the level
of ACh in cholinergic synapses and can therefore
influence different pathological processes. Defects
in cholinergic neurotransmission are significant for
the progression of Alzheimerís disease (AD) and
other pathological processes. According to the
cholinergic hypothesis of AD, many symptoms of
dementia, especially learning and memory difficul-
ties, were explicable by the lack of ACh (2). Thus,
cholinesterase inhibitors that improve cholinergic
neurotransmission in the synaptic cleft were devel-
oped as therapeutic agents for the treatment of AD.
The first drug approved for the treatment of AD was
tacrine. Currently, three other cholinesterase
inhibitors: rivastigmine, donepezil and galantamine
are available on the market and are used as sympto-
matic therapy of AD (3). In spite of limited efficacy
of cholinergic therapy, both cholinesterases still
remain valuable targets in search for new agents
against AD (4, 5). That is due to their additional,
non-hydrolytic properties associated with β-amyloid
(Aβ) and neurofibrillary tangles formation, which
are important for AD pathogenesis (6-8). In recent
years, many inhibitors of AChE or both AChE and
BuChE have been developed (9, 10). Among differ-
ent approaches for the design of novel
cholinesterase inhibitors virtual screening tech-
niques have also been applied (11-13). Our studies
focus on the design, synthesis and biological evalu-
ation of potential cholinesterase inhibitors and mul-
tifunctional ligands with cholinesterase inhibitory
activity (14-18). The aim of this study was to design
new potential dual binding site cholinesterase
inhibitors using a virtual screening method, synthe-
size the selected compounds, test their AChE and
BuChE inhibitory activity and select hits for further
development.
RESULTS AND DISCUSSION
Data set for virtual screening
A two-step virtual screening of the ZINC data-
base was applied for the identification of new
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cholinesterase inhibitors. The ZINC database is a
free data set of commercially available compounds,
serving to virtual screening. The latest version of the
database (ZINC 12) contains over 35 million com-
pounds and is provided by the Shoichet Laboratory
from the University of California (19). The ZINC
database is a huge source of compounds to search
for new active substances and therefore it was cho-
sen to search for new cholinesterase inhibitors.
ZINC 8, which was available at the time of the
screening carried out for this study, contained 8.5
million compounds. The two-step virtual screening
was preceded by a prefiltering of compounds, which
was based on the physicochemical properties,
important for proper absorption and distribution to
the central nervous system (20, 21), as described in
the Experimental part. This prefiltering left 65396
compounds for the subsequent virtual screening. 
Creation of pharmacophore models
Wolber suggested application of crystal struc-
tures from PDB (22) for creation of pharmacophore
models (23, 24). As similar methodology was
applied in the presented studies. Different PDB files
were used to assign pharmacophore features with
the MOE program (25). In the case of acetyl-
cholinesterase, for creation of pharmacophore mod-
els we utilized crystal structures of the enzyme com-
plexes with four inhibitors: donepezil, bis-tacrine,
decamethonium and tacrine (Fig. 1).
The biologically active conformation, derived
from the crystal complexes was used directly to gen-
erate the models. Based on how these four inhibitors
bound with AChE, the specific interactions were
included in the pharmacophore models. The model
for donepezil took into account two aromatic fea-
tures and one cation ñ donor, the model for bis-
tacrine two aromatic and two cation ñ donor fea-
tures, the model for decamethonium two cation fea-
tures and the model for tacrine one aromatic and one
cation ñ donor feature (Fig. 2).
To generate a pharmacophore model for
butyrylcholinesterase inhibitors, a different method
was used due to the lack of crystal structures of
BuChE complexes with inhibitors interacting in a
non-covalent manner at that time. The research was
undertaken on the basis of bis-nor-meptazinol, which
is a potent inhibitor of both cholinesterases (Fig. 1)
(26). The possible interactions of this compound
with both enzymes, determined by molecular model-
ing techniques were widely described in the literature
(27). The structure of this inhibitor was optimized
with the program MOE (27) using the MMFF94
force field and then used for creation of a pharma-
Figure 1. Chemical structure of the selected cholinesterase inhibitors used for the development of pharmacophore models
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cophore model, taking into account two aromatic and
two cationic / H-bond donors features (Fig. 3).
Screening with the pharmacophore models
The compounds from the ZINC database were
optimized with MOE program, using the MMFF94
force field and then screened with the previously
created pharmacophore models. As a measure of a
fit quality of the compounds the root-mean-square
deviation (rmsd) value was used with respect to the
center of each feature of the model (Table 1).
The pharmacophore screening yielded 88 com-
pounds for the donepezil model, 12 for decametho-
nium and 5102 for tacrine. Models for tacrine and
decamethonium were two-point pharmacophores
and screening with them resulted in too many com-
pounds. Therefore, only compounds chosen with the
donepezil model were used in further studies.
Figure 2. The pharmacophore models for donepezil, tacrine, bis-(7)-tacrine and decamethonium (the features were marked as follows: aro-
matic ring - Aro, cation and H-bond donor ñ Cat&Don, cation - Cat)
Table 1. The results of virtual screening with the pharmacophore models for the selected AChE and BuChE inhibitors.
Enzyme Pharmacophore model Number of hits Rmsd value range []
Donepezil 88 0.13 - 0.79
bis-7-Tacrine 0 - 
AChE 
Decamethonium 12 0.28 - 0.91
Tacrine 5102 0.015 - 1.00
BuChE bis-nor-Meptazinol 0 -
Rmsd = root-mean-square deviation
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Screening with docking
The 88 compounds, which passed the pharma-
cophore screening with the donepezil model, were
selected for docking to acetylcholinesterase. The
aim of this procedure was an accurate selection of
hits and search for additional interactions in the
active gorge of the enzyme. The next criterion for
compound selection was the score obtained with the
scoring function ChemScore. Donepezil, used as a
reference, obtained a ChemScore value of 49.48.
Compounds with a scoree above 43 were chosen for
further studies, and the results are summarized in
Table 2. Comparison of the scoring function value
for the selected hits with the result for donepezil
suggested that all of them would probably be less
active than the reference compound.
Structures of the selected hits 1-7 are shown in
Figure 4. According to literature data, they have not
been tested against cholinesterases so far, therefore
the chosen compounds were a good starting point to
search for new inhibitors. Compounds 2 and 4 were
selected for synthesis, while the remaining com-
pounds were purchased. 
Chemistry 
Scheme 1A describes the procedure used for the
synthesis of compound 2. At first, 1H-indole-3-car-
baldehyde 8 was obtained by the formylation of 1H-
indole, using POCl3 and DMF as a reagent and a sol-
vent (28). In the next step, the reductive condensation
of compound 8 with piperazine was carried out in the
presence of acetic acid and NaBH4 in methanol (29).
In the parallel pathway phenol was converted into
sodium phenoxide using sodium hydroxide and then
reacted with iodoacetic acid giving phenoxyacetic
acid 10. Compound 10 was subsequently converted
into the acid chloride 11 in the reaction with thionyl
chloride, and was used as an acylation agent. The
final product was obtained in the reaction of 3-(piper-
azin-1-ylmethyl)-1H-indole 9 with the phenoxyacetic
acid chloride 11. The reaction was carried out in dry
THF at room temperature followed by the purifica-
tion by silica gel column chromatography. The final
compound 1-[4-(1H-indol-3-ylmethyl)piperazin-1-
yl]-2-phenoxyethanone 2 was isolated as a red oil and
then converted into a hydrochloride salt. The synthe-
sis of compound 4 was accomplished in two steps and
it is presented in Scheme 1B. In the first step, 2-
bromo-1-phenylethanol 12 was synthesized from
styrene by bromination of the alkyl chain. The reac-
tion was carried out using N-bromosuccinamide as a
brominating agent in a mixture of water and acetoni-
trile at room temperature. In the next step, compound
12 was used for alkylation of 1-benzylpiperidine-4-
amine. The reaction was performed in acetonitrile, in
the presence of potassium carbonate under reflux
(30). Then the crude product was purified by silica
Figure 3. The pharmacophore model for bis-nor-meptazinol (aromatic ring - Aro, cation and H-bond donor ñ Cat&Don)
Table 2. Compounds from the ZINC database selected in virtual screening with the donepezil pharmacophore
model and docking.
Comp. No. Symbol ChemScore
1 ZINC00207679 45.57
2 ZINC0015483 45.22
3 ZINC00146717 44.17
4 ZINC00152443 44.04
5 ZINC00110981 43.99
6 ZINC00087269 43.81
7 ZINC00212881 43.26 
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gel column chromatography. The final compound 4
was isolated as colorless oil, and then converted into
a hydrochloride salt. 
Biological activity
The activity of the compounds selected from vir-
tual screening (1ñ7) was tested against EeAChE
(AChE from Electrophorus electricus) and EqBuChE
(BuChE from horse serum) in the spectrometric
method established by Ellman et al. (29). Ellmanís test
is based on the reaction of 5,5í-dithiobis-(2-nitroben-
zoic) acid (DTNB, Ellmanís reagent) with thiocholine,
which is the product of hydrolysis of acetylthiocholine
(ATC) or butyrylthiocholine (BTC), by AChE or
BuChE, respectively. The screening concentration
was 100 µM for the compounds soluble in water (1, 2,
4, 5 and 7) and 1 µM for the compounds tested with
addition of DMSO (3, 6). The obtained results for the
Figure 4. Structures of potential cholinesterase inhibitors selected from the ZINC database by virtual screening technique
Table 3. Inhibitory activity of the tested compounds against EeAChE and EqBuChE.
Compound EeAChE EqBuChE
% inhibition IC50 [µM] % inhibition  IC50 [µM]
1 8.47a - n. a.a -
2 8.87a - 50.09a -
3 n. a.b - n. a.b -
4 17.71a - 79.48a -
5 n. a.a - n. a.a -
6 n. a.b - n. a.b -
7 n. a.a - n. a.a -
Donepezil 93.06b 0.031 24.36b 2.84
Tacrine 93.77b 0.050 99.44b 0.0054  
a The screening concentration of 100 µM. b The screening concentration of 1 µM; n. a. ñ not active, the percentage of inhibition lower than 5%.
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tested compounds and the references (tacrine and
donepezil) are presented in Table 3.
Very low activity or complete lack of activity of
the tested compounds in a relatively high concentration
of 100 µM (except for 3 and 6, which were tested at 1
µM due to solubility problems) makes us define them as
inactive towards AChE. On the other hand, two of the
compounds, 2 and 4, exhibited above 50% of inhibition
at the concentration of 100 µM against BuChE.
Compounds 2 and 4 belong to different structural class-
es. Compound 2 is an indole derivative with a piperazine
group and an additional phenyl ring, whereas compound
4 contains N-benzylpiperidine moiety, which is a char-
acteristic pharmacophore fragment occurring in the
cholinesterase inhibitors like donepezil. The obtained
results indicate that compounds 2 and 4 could be
described as relatively weak inhibitors of BuChE.
However, structures of these compounds provide ample
opportunities for modifications that can improve their
activity so that they can become good lead structures for
the search of new cholinesterase inhibitors. 
SUMMARY
Virtual screening performed on the compounds
from the ZINC database enabled us to select over 
65 000 potential cholinesterase inhibitors with opti-
mal physicochemical properties. An application of a
pharmacophore model for donepezil and then dock-
ing to AChE led to a selection of 7 structures for fur-
ther studies. The activity of the selected compounds
against AChE and BuChE was tested using the
Ellmanís test. None of the compounds displayed
activity against AChE and two of them, 2 and 4,
were weak inhibitors of BuChE. The lack of the
activity against AChE is probably the result of a too
tolerant selection criterion based on a scoring func-
tion value, which was lower than that for the refer-
ence compound - donepezil. Moreover, the number
of the tested compounds was very limited. However,
it is worthy to note that the applied method of dock-
ing to AChE has been previously used with success
and led to the design of potent AChE inhibitors in
the group of isoindoline-1,3 derivatives (17, 18).
The identification of compounds 2 and 4 as
BuChE inhibitors is an interesting result of this
study. Even though their activity is rather weak
when compared with the reference compounds, they
can be subject to further modifications, which may
increase their activity. Such methodology is accept-
ed during a drug discovery project, where at the
beginning, even a low activity of a hit compound is
a good starting point for further development. 
EXPERIMENTAL
Molecular modeling
Virtual screening
The initial selection of compounds was based
on physicochemical properties, important for proper
Scheme 1. The synthesis of compounds 2 and 4. Reagents and conditions: A. (a) POCl3, DMF, 0-35
OC, 2 h; (b) piperazine, NaBH4,
CH3COOH, CH3OH, 65
OC, r.t., 24 h; (c) ICH2COOH, NaOH, H2O, 10-100
OC, 1.5 h; (d) SOCl2, 75
OC, 4 h; (e) THF, r.t., 2 h. B. (a) N-bro-
mosuccinimide, CH3CN/H2O, r.t., 20 h; (b) K2CO3, CH3CN, 81
OC, 48 h
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absorption and distribution to the central nervous
system (20, 21). Accordingly, structures were cho-
sen for which:
1 ≤ charge after ionization ≤ 3
1 ≤ logP ≤ 3
number of rotatable bonds ≤ 8
1 ≤ number of hydrogen bond donors ≤ 5
1 ≤ number of hydrogen bond acceptors ≤ 10
100 ≤ molecular weight (MW) ≤ 500.
This led to 65396 compounds, including their
isomers. They were downloaded from the ZINC
database (19) in SMILES format, which further
served to build 3D structures by the Corina stand-
alone version (32). Finally, the compounds were
saved in the mol2 format. At this step of the study,
a two-stage screening methodology was applied.
The first stage used pharmacophore models and the
second one was based on the docking process of the
selected molecules. Pharmacophore models were
generated with the MOE 2008.10 program (25).
Features were assigned based on the interactions
pattern of the reference inhibitors, some features
were assigned. The active conformations of AChE
ligands were obtained directly from PDB crystal
complexes (22), and in case of butyryl-
cholinesterase inhibitor it was drawn and optimized
in MMFF94 force field with MOE 2008.10.
Structures of the compounds selected for screening
were also optimized in the same way. As a measure
of fit quality of the compounds, the rmsd value with
respect to the center of each model feature was
used. Dockings to acetylcholinesterase were per-
formed according the procedure described previ-
ously (18). During the protein preparation (PDB:
1EVE) (22) all the histidine residues were protonat-
ed at Nε, hydrogen atoms were added, ligands were
removed, the binding site was defined as all amino
acid residues within 10  from donepezil and three
water molecules (1159, 1249, 1254) were included.
Dockings were performed with Gold 4.0 (33). A
standard setting of the genetic algorithm with a
population size 100, a number of operations of
100000 and a clustering with a tolerance of 1 was
applied. ChemScore was used for evaluation of the
docking results. For each ligand the final results
involved 10 poses, arranged on the ranking list
according to the scoring function values.
Chemistry
All solvents and reagents were purchased from
commercial suppliers and were used without further
purification. Compound 1 was purchased from
Vitas-M Laboratory Ltd., compounds 3, 5, 6 and 7
were purchased from Molport. Column chromatog-
raphy was performed on Merck silica gel 60
(63ñ200 µm). Analytical thin layer chromatography
was done using aluminum sheets precoated with sil-
ica gel 60 F254. Analytical RPLC-MS was performed
on Waters Acquity TQD with a mass spectrometer
(Waters TQD, Milford, MA, USA) with detection
by UV (DAD) using an Acquity UPLC BEH C18
column (1.7 µm, 2.1 ◊ 100 mm). CH3CN/H2O gra-
dient with 0.1% HCOOH was used as the mobile
phase at a flow rate of 0.3 mL/min. 1H NMR spectra
were recorded on Varian Mercury 300 at 300 MHz.
The chemical shifts for 1H NMR are referenced to
TMS via residual solvent signals (1H, CDCl3 at 7.26
ppm, (CD3)2SO at 2.50 ppm). All the compounds
showed purity above 95%. Compounds 4, 8 and 9
were previously reported (28ñ30).
1H-Indole-3-carbaldehyde (8)
To a solution of POCl3 (5.00 mmol, 767 mg) in
DMF (8.5 mL) at 10OC, a solution of indole (5.00
mmol, 586 mg) in 5 mL of DMF was added. The
reaction mixture was stirred at this temperature for 1
h and then for 1 h at 35OC. To the resulting mixture
20 g of ice was added and then it was alkalized by
aqueous solution of NaOH (5.65 g in 15 mL). The
precipitate was filtered, washed and recrystallized
from water to give 1H-indole-3-carbaldehyde 8 as a
pink solid (yield: 71%). Rf (chloroform/methan-
ol/NH3; 8 : 1 : 0.1, v/v/v) 0.51; 1H NMR (300 MHz,
DMSO-d6, δ, ppm): 9.93 (s, 1H, CHO), 8.25-8.31
(m, 1H, H2), 8.03-8.13 (m, 1H, H9), 7.45-7.57 (m,
1H, H6), 7.16-7.33 (m, 2H, H7,8), 1NH - not detect-
ed; MS: m/z 146.03 [M + H+]; purity: 100% (by
HPLC); Mol. form. C9H7NO. 
3-(Piperazin-1-ylmethyl)-1H-indole (9)
To a solution of 1H-indole-3-carbaldehyde 8
(1.03 mmol, 150 mg) and piperazine (5.17 mmol,
445 mg) in 7.0 mL of methanol, acetic acid (2.07
mmol, 118 µL) was added. The reaction mixture was
stirred under reflux for 1 h. In the next step, after
cooling the reaction mixture to room temperature,
sodium borohydride (1.55 mmol, 58 mg) was added
and then the mixture was stirred at room tempera-
ture overnight. Subsequently, the solvent was evap-
orated and the residue was purified by column chro-
matography on silica gel (chloroform/methan-
ol/NH3; 8 : 1 : 0.1, v/v/v) to give the desired product
as a red oil (yield: 52%). Rf (chloroform/methan-
ol/NH3; 8 : 1 : 0.1, v/v/v) 0.21; 1H NMR (300 MHz,
CDCl3, δ, ppm): 8.25 (s, 1H, 1NH), 7.74 (qd, J =
0.73, 7.82 Hz, 1H, H4), 7.31-7.44 (m, 1H, H7),
7.04-7.23 (m, 3H, H2,5,6), 3.73 (d, J = 0.77 Hz, 2H,
CH2α), 2.83-3.00 (t, 4H, 3CH2í, 5CH2í), 2.52 (br. s.,
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4H, 2CH2í, 6CH2í), 4íNH - not detected; MS: m/z
216.22 [M + H+]; purity: 98% (by HPLC); Mol.
form. C13H17N3.
Phenoxyacetic acid (10)
To a solution of iodoacetic acid (12.50 mmol,
2328 mg) in 15.0 mL of water an aqueous solution of
NaOH (535 mg in 2.0 mL) was added dropwise at
10OC. Subsequently, phenol (12.50 mmol, 1178 mg)
was added and then, again the same amount of an
aqueous solution of NaOH was added dropwise. The
reaction mixture was refluxed for 1-2 h. After the
reaction was finished, the mixture was cooled by the
addition of 10.0 mL of water and then the resulting
precipitate was filtered. The crude residue was
recrystallized from water to give phenoxyacetic acid
10 as a white solid (yield: 28%); Rf (DCM/methan-
ol/acetic acid; 9 : 1 : 0.1, v/v/v) 0.41; 1H NMR (300
MHz, CDCl3, δ, ppm): 7.27-7.37 (t, 2H, H2,3), 6.99-
7.08 (t, 1H, H4), 6.88-6.97 (d, 2H, H3,5), 4.69 (s, 2H,
CH2α), COOH - not detected; MS: m/z 153.07 [M +
H+]; purity: 100% (by HPLC); Mol. form. C8H8O3.
1-[4-(1H-Indol-3-ylmethyl)piperazin-1-yl]-2-phe-
noxyethanone (2)
A solution of phenoxyacetic acid 10 (0.99
mmol, 150 mg) in 1.0 mL of thionyl chloride was
refluxed for 3 h under argon atmosphere. Then, the
solvent was removed and the residue was dissolved
in 1.0 mL of THF. The resulting solution of the
obtained 2-phenoxyacetyl chloride 11 was added
dropwise to a solution of 3-(piperazin-1-ylmethyl)-
1H-indole 9 (1.00 mmol, 215 mg) in 5.0 mL of THF.
Subsequently, the reaction mixture was stirred at
room temperature for 2 h. The solvent was evapo-
rated and the residue was purified by column chro-
matography (DCM/methanol, gradient from 1 : 0 to
0.9 : 0.1, v/v) to afford the pure product as a red oil
(yield: 89%); Rf (DCM/methanol 0.9 : 1, v/v) 0.37;
1H NMR (300 MHz, methanol-d4, δ, ppm): 7.65 (dt,
J = 0.93, 7.89 Hz, 1H, H4íí), 7.33-7.43 (d, 1H,
H7íí), 7.03-7.27 (m, 4H, H3,5,2î,6î), 6.78-6.98 (m,
4H, H2,4,6,5íí), 4.75 (s, 2H, CH2α), 4.21 (s, 2H,
NCH2), 3.64-3,77 (br. s., 4H, H2í,6í), 2.86-3.10 (br.
s., 4H, H3í,5í), 1ííNH - not detected; MS: m/z
350.30 [M + H+]; purity: 97% (by HPLC); Mol.
form. C21H23N3O2.The final product was converted
into a hydrochloride salt.
2-Bromo-1-phenylethanol (12)
To a stirred solution of styrene (8.70 mmol,
906 mg) in 18.0 mL of acetonitrile the solution of N-
bromopyrrolidine-2,5-dione (8.70 mmol, 1550 mg)
in 18.0 mL of water was added dropwise at room
temperature. After stirring at room temperature for
20 h, acetonitrile was evaporated and then 20.0 mL
of water was added. The resulting mixture was
washed with DCM (1 ◊ 20.0 mL, 2 ◊ 15.0 mL) and
ethyl acetate (1 ◊ 20.0 mL). The organic phase was
dried over anhydrous sodium sulfate and evaporated
to dryness. The obtained residue was purified on a
silica gel by column chromatography (petroleum
ether/ethyl acetate 9.6 : 0.4, v/v) to provide the pure
product as a colorless oil (yield: 37%); Rf (petrole-
um ether/ethyl acetate 9.6 : 0.4, v/v) 0.23; 1H NMR
(300 MHz, CDCl3, δ, ppm): 7.28-7.44 (m, 5H,
H2,3,4,5,6), 4.93 (dd, J = 3.33, 8.98 Hz, 1H, CHα),
3.61-3.70 (m, 1H, CHβ), 3.46-3.60 (m, 1H, CHíβ),
2.66 (s, 1H, OH); MS: m/z 183.05 [M - 18 + H+];
purity: 95% (by HPLC); Mol. form. C8H9BrO.
2-[(1-Benzylpiperidine-4-yl)amino]-1-phenyl-
ethanol (4)
A solution of 2-bromo-1-phenylethanol 12
(1.49 mmol, 300 mg), 1-benzylpiperidine-4-amine
(1.49 mmol, 284 mg) and potassium carbonate (4.47
mmol, 615 mg) in 20.0 mL of acetonitrile was
stirred under reflux for 20 h. After the reaction was
finished, acetonitrile was evaporated and the result-
ing mixture was dissolved in DCM and washed with
water (1 ◊ 15.0 mL, 2 ◊ 10.0 mL). The organic
phase was dried over anhydrous sodium sulfate and
evaporated to dryness. The obtained crude product
was purified by column chromatography (DCM/
methanol 0.9 : 0.1, v/v) to provide the pure product
as a colorless oil (yield: 58%); Rf (DCM/ methanol
0.9 : 0.1, v/v) 0.26; 1H NMR (300 MHz, CDCl3, δ,
ppm): 7.16-7.43 (m, 10H, H2,3,4,5,6,2íí,3íí,4íí,
5íí,6íí), 4.75 (dd, J = 3.33, 9.23 Hz, 1H, CHα),
3.48-3.51 (s, 2H, NCH2), 2.66-3.15 (m, 7H, CH2
2í,6í,β, OH), 2.49-2.65 (m, 1H, CH 4í), 1.81-2.11
(m, 4H, CH2 3í,5í), NH - not detected; MS: m/z
311.25 [M + H+]; purity: 99% (by HPLC); Mol.
form. C20H26N2O. The final product was converter
into a hydrochloride salt. 
Biological activity - Ellmanís test (31)
Reagents and chemicals: 5,5í-dithiobis(2-
nitrobenzoic) acid (DTNB, Ellmanís reagent),
acetylthiocholine iodide (ATCh), butyrylthiocholine
iodide (BTCh), AChE from Electrophorus electricus
(425.96 U/mg solid), and BuChE from horse serum
(2.5 units/1 mL) were purchased from Sigma-
Aldrich. The measurement of absorbance was per-
formed using the Perkin Elmer Lambda 12 appli-
ance or EnSpire Multimode Microplate Reader
PerkinElmer. The detection wavelength was 412
nm. Due to different solubility, compounds 1, 2, 4, 5
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and 7 were dissolved in water and measured at 100
µM concentration, while compounds 3 and 6 were
dissolved in 1% solution of DMSO and experiments
were carried out in a 1 µM concentration. The test-
ed compounds were incubated with an enzyme at
25OC for 5 min before starting the reaction. The
experiment was performed in 100 mM phosphate
buffer (pH 8.0) containing 0.25 units of AChE or
BuChE using 0.45 mmol ATCh or BTCh and 0.2
µM DTNB as substrates. The experiments were per-
formed in triplicate.
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